Effect of goji berry on the formation of extracellular senile plaques of Alzheimer’s disease
Authors:
Open Access
- 7 June 2021
- journal article
- research article
- Published by SAGE Publications in Nutrition and Healthy Aging
- Vol. 6 (2) , 105-116
Abstract
BACKGROUND: Alzheimer’s disease (AD) is the most common neurodegenerative disease and a major source of morbidity and mortality. Currently, no therapy nor drug can cure or modify AD progression, but recent studies suggest that nutritional compounds in certain foods can delay or prevent the onset of AD. Diets with high antioxidants is one of the examples which is believed to influence AD pathogenesis through direct effect on amyloid beta levels. Compared to other fruits and vegetables, goji berry (GB) has high levels of polyphenolic substances with antioxidant activities which have shown some positive effects on cognitive function while its mechanism on neuroprotection is yet to be explored. We investigated whether GB would decrease the quantity of amyloid beta in cell culture model of AD. OBJECTIVE: To assess the protective effects of GB against amyloid beta toxicity in M17 cells using different techniques. METHODS: Goji berry powder (GBP) at different concentrations was treated with 20 μM amyloid beta-induced neuronal cells. MTS assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium), bicinchoninic acid (BCA) assay, Western blot analysis, enzyme-linked immunosorbent assay (ELISA) and atomic force microscopy (AFM) were performed to identify how GB affected amyloid beta. RESULTS: MTS assay indicated that GBP significantly increased cell viability up to 105% when GBP was at 1.2 μg/ mL. Western blot showed significant reduction of amyloid beta up to 20% in cells treated with 1.5 μg/ mL GBP. GBP at 1.5 μg/ mL was the most effective concentration with 17% reduction of amyloid beta in amyloid beta-induced neuronal cells compared to control (amyloid beta only) based on ELISA results. AFM images further confirmed increasing GBP concentration led to decreased aggregation of amyloid beta. CONCLUSION: GB can be a promising anti-aging agent and warrants further investigating due to its effect on reduction of amyloid beta toxicity.Keywords
This publication has 34 references indexed in Scilit:
- Amyloid β Levels in Human Red Blood CellsPLOS ONE, 2012
- Characterisation of antioxidant and antiproliferative acidic polysaccharides from Chinese wolfberry fruitsFood Chemistry, 2012
- Lycium barbarum Extracts Protect the Brain from Blood-Brain Barrier Disruption and Cerebral Edema in Experimental StrokePLOS ONE, 2012
- Unraveling the Early Events of Amyloid-β Protein (Aβ) Aggregation: Techniques for the Determination of Aβ Aggregate SizeInternational Journal of Molecular Sciences, 2012
- Lycium barbarum Polysaccharides Reduce Exercise-Induced Oxidative StressInternational Journal of Molecular Sciences, 2011
- Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Clinical Study of the General Effects of a Standardized Lycium barbarum (Goji) Juice, GoChi ™The Journal of Alternative and Complementary Medicine, 2008
- Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicityExperimental Gerontology, 2005
- Pathways towards and away from Alzheimer's diseaseNature, 2004
- A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neuronsBiochemical Journal, 2003